GLP-1 Spending and the Case for Comprehensive Cardiometabolic Care

Employer healthcare costs are projected to rise 8.2% per employee in 2027, with growing GLP-1 utilization adding to the pressure.¹ As employers reconsider coverage and tighten utilization controls,² the challenge extends beyond medication costs to the long-term management of obesity, diabetes, hypertension, and high cholesterol.

Our latest white paper examines the financial and clinical considerations shaping GLP-1 strategies, the evidence behind comprehensive cardiometabolic care, and new findings from Sword's GLP-1 wraparound pilot.

A closer look at the costs, risks, and opportunities

Inside the white paper, discover:

• The changing cost of GLP-1 coverage: Why employers are tightening utilization controls and rethinking their benefits strategies heading into 2027.²
• The clinical risks beyond weight loss: What research reveals about medication discontinuation, weight regain,⁵ and changes in lean mass during treatment.⁶
• The case for connected cardiometabolic care: Why clinical guidance supports combining GLP-1 treatment with structured nutrition and physical activity interventions,⁷ and how comprehensive care can address broader cardiometabolic needs.
• New findings from Sword's GLP-1 pilot: What member engagement, strength-training participation, and reported health improvements reveal about comprehensive support during treatment.⁴